Medicines regulation and law
FDA to take new approach on homeopathic products
The US Food and Drug Administration (FDA) is set to introduce a new ‘risk-based enforcement approach’ to homeopathic drugs in America, in a bid to protect consumers who choose to use alternative treatments.
The US Food and Drug Administration (FDA) is to a new ‘risk-based enforcement approach’ to drug products that are labeled ‘homeopathic’ and available on the American market.
In a bid to protect consumers who choose to use homeopathic products, the FDA is set to update existing policy to try to better address situations where homeopathic treatments are being marketed for serious diseases or conditions, but where the products have not been shown to offer clinical benefits.
Its new policy will cover products labelled as homeopathic but which contain potentially harmful ingredients or which do not meet good manufacturing practices.
Current US law stipulates that homeopathic drug products are subject to the same requirements related to approval, adulteration and misbranding as any other drug product. However, prescription and non-prescription drug products labelled as homeopathic have been manufactured and distributed without FDA approval under the since 1988.
“In many cases, people may be placing their trust and money in therapies that may bring little to no benefit in combating serious ailments, or worse — that may cause significant and even irreparable harm because the products are poorly manufactured, or contain active ingredients that aren’t adequately tested or disclosed to patients,” warned FDA commissioner, Scott Gottlieb.
“Our approach to regulating homeopathic drugs must evolve to reflect the current complexity of the market, by taking a more risk-based approach to enforcement. We respect that some individuals want to use alternative treatments, but the FDA has a responsibility to protect the public from products that may not deliver any benefit and have the potential to cause harm.”
Examples of products that may be subject to the enforcement priorities in the draft guidance are infant and children’s products labeled to contain ingredients associated with potentially significant safety concerns, such as belladonna and nux vomica; and products marketed for serious conditions, such as cancer and heart disease.
Citation: The Salvadore DOI: 10.1211/PJ.2018.20204172
Recommended from Pharmaceutical Press
FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.£25.00
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00
A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.£54.00
The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.£25.00
The Handbook of Pharmaceutical Excipients contains essential data on the physical properties of excipients, their safe use and potential toxicity.£415.00